Your browser doesn't support javascript.
loading
Postoperative radiotherapy for WHO grade II-III intracranial ependymoma in adults: An intergroup collaborative study (KROG 18-06/KNOG 18-01).
Wee, Chan Woo; Kim, Il Han; Park, Chul-Kee; Lim, Do Hoon; Nam, Do-Hyun; Yoon, Hong In; Suh, Chang-Ok; Chang, Jong Hee; Chung, Woong-Ki; Jung, Tae-Young; Park, Shin-Hyung; Kim, Chae-Yong; Kim, Young Zoon; Gwak, Ho Shin; Cho, Kwan Ho; Kim, Jin Hee; Im, Jung Ho; Kim, Woo Chul; Kim, Sung-Hwan; Kim, In Ah.
Afiliación
  • Wee CW; Department of Radiation Oncology, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea.
  • Kim IH; Department of Radiation Oncology, Seoul National University Hospital, Republic of Korea.
  • Park CK; Department of Neurosurgery, Seoul National University Hospital, Republic of Korea.
  • Lim DH; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Nam DH; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Yoon HI; Department of Radiation Oncology, Yonsei Cancer Center, Seoul, Republic of Korea.
  • Suh CO; Department of Radiation Oncology, Yonsei Cancer Center, Seoul, Republic of Korea.
  • Chang JH; Department of Neurosurgery, Yonsei Cancer Center, Seoul, Republic of Korea.
  • Chung WK; Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea.
  • Jung TY; Department of Neurosurgery, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea.
  • Park SH; Department of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Kim CY; Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Kim YZ; Division of Neuro-Oncology and Department of Neurosurgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
  • Gwak HS; Department of Neurosurgery, National Cancer Center, Goyang, Republic of Korea.
  • Cho KH; Proton Therapy Center, National Cancer Center, Goyang, Republic of Korea.
  • Kim JH; Department of Radiation Oncology, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea.
  • Im JH; Department of Radiation Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
  • Kim WC; Department of Radiation Oncology, Inha University Hospital, Incheon, Republic of Korea.
  • Kim SH; Department of Radiation Oncology, St. Vincent's Hospital, Suwon, Republic of Korea.
  • Kim IA; Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Electronic address: inah228@snu.ac.kr.
Radiother Oncol ; 150: 4-11, 2020 09.
Article en En | MEDLINE | ID: mdl-32502505
BACKGROUND AND PURPOSE: To evaluate the impact of adjuvant postoperative radiotherapy (PORT) in adult WHO grade II-III intracranial ependymoma (IEPN). MATERIALS AND METHODS: A total of 172 pathologically confirmed adult grade II-III IEPN patients from 12 institutions were eligible. Of them, 106 (61.6%) and 66 (38.4%) patients were grade II and III, respectively. For grade II and III IEPNs, 51 (48.1%) and 59 (89.4%) patients received PORT, respectively. The median dose to the primary tumor bed was 54.0 Gy and 59.4 Gy for grade II and III patients, respectively. The prognostic impact of sex, age, performance, WHO grade, location, size, surgical extent, and PORT on local control (LC), progression-free survival (PFS), and overall survival (OS) were evaluated by univariate and multivariate analysis. RESULTS: The median follow-up period for survivors was 88.1 months. The 5-/10-year LC, PFS, and OS rates were 64.8%/54.0%, 56.4%/44.8%, and 76.6%/71.0%, respectively. On multivariate analysis, adjuvant PORT significantly improved LC (P = 0.002), PFS (P = 0.002), and OS (P = 0.043). Older age (P < 0.001), WHO grade III (P < 0.001), larger tumor size (P = 0.004), and lesser surgical extent (P < 0.001) were also negative factors for OS. Adjuvant PORT also improved LC (P = 0.010), PFS (P = 0.007), and OS (P = 0.069) on multivariate analysis for grade II IEPNs. CONCLUSION: This multicenter retrospective study supports the role of adjuvant PORT in terms of disease control and survival in adult grade II-III IEPNs. Prospective randomized trials focused on individualized treatment based on molecular subtypes is warranted.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ependimoma Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Aged / Humans Idioma: En Revista: Radiother Oncol Año: 2020 Tipo del documento: Article Pais de publicación: Irlanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ependimoma Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Aged / Humans Idioma: En Revista: Radiother Oncol Año: 2020 Tipo del documento: Article Pais de publicación: Irlanda